Barclays PLC Has $4.43 Million Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Barclays PLC increased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 140.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,381 shares of the biopharmaceutical company's stock after purchasing an additional 76,207 shares during the quarter. Barclays PLC owned approximately 0.20% of Celldex Therapeutics worth $4,431,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in CLDX. Y Intercept Hong Kong Ltd raised its position in Celldex Therapeutics by 11.5% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company's stock valued at $1,038,000 after purchasing an additional 3,146 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Celldex Therapeutics in the third quarter valued at about $1,561,000. Wellington Management Group LLP lifted its position in Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock worth $314,190,000 after buying an additional 1,167,659 shares in the last quarter. Sphera Funds Management LTD. grew its holdings in Celldex Therapeutics by 35.5% during the 3rd quarter. Sphera Funds Management LTD. now owns 419,103 shares of the biopharmaceutical company's stock worth $14,245,000 after acquiring an additional 109,838 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new stake in Celldex Therapeutics in the 3rd quarter valued at about $6,102,000.

Insider Activity

In other news, CEO Anthony S. Marucci bought 11,500 shares of the stock in a transaction on Monday, November 11th. The stock was purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CLDX. Wolfe Research lowered shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a report on Friday, September 27th. Citigroup began coverage on Celldex Therapeutics in a research note on Monday, October 7th. They set a "buy" rating and a $70.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday. Finally, Wells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $62.25.

Celldex Therapeutics Price Performance

CLDX traded down $0.24 during mid-day trading on Friday, hitting $25.14. The stock had a trading volume of 2,166,760 shares, compared to its average volume of 891,722. The stock's fifty day simple moving average is $26.79 and its 200-day simple moving average is $33.36. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -9.78 and a beta of 1.57. Celldex Therapeutics, Inc. has a 1-year low of $22.93 and a 1-year high of $53.18.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.